Sinopharm Group Co Ltd
SWB:X2S
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sinopharm Group Co Ltd
SWB:X2S
|
CN |
|
P
|
Petroleo Brasileiro SA Petrobras
XMUN:PJX
|
BR |
|
G
|
Groep Brussel Lambert NV
XMUN:EAI
|
BE |
|
B
|
Bank of America Corp
SWB:NCB
|
US |
|
A
|
AECOM
SWB:E6Z
|
US |
|
S
|
Surmodics Inc
SWB:SU6
|
US |
|
Q
|
Qualcomm Inc
F:QCI
|
US |
|
F
|
Federal Realty Investment Trust
F:WX2
|
US |
Wall St Price Targets
X2S Price Targets Summary
Sinopharm Group Co Ltd
According to Wall Street analysts, the average 1-year price target for X2S is 2.514 EUR with a low forecast of 2.025 EUR and a high forecast of 3.069 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is X2S's stock price target?
Price Target
2.514
EUR
According to Wall Street analysts, the average 1-year price target for X2S is 2.514 EUR with a low forecast of 2.025 EUR and a high forecast of 3.069 EUR.
What is the Revenue forecast for Sinopharm Group Co Ltd?
Projected CAGR
6%
Over the last 14 years, the compound annual growth rate for Revenue has been 13%. The projected CAGR for the next 3 years is 6%.
What is the Operating Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
26%
Over the last 14 years, the compound annual growth rate for Operating Income has been 11%. The projected CAGR for the next 3 years is 26%.
What is the Net Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
10%
Over the last 14 years, the compound annual growth rate for Net Income has been 11%. The projected CAGR for the next 3 years is 10%.
